Thyroid transcription factor 1 expression is associated with
outcome of patients with non-squamous non-small cell lung
cancer treated with pemetrexed-based chemotherapy

J 2017

Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy

FIALA, Ondrej; Milos PESEK; Jana SKŘIČKOVÁ; Vitezslav KOLEK; Frantisek SALAJKA et al.

Základní údaje

Originální název

Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy

Autoři

Vydání

Tumor Biology, Dordrecht, Springer, 2017, 1010-4283

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 3.650 v roce 2016

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/17:00096514

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Thyroid transcription factor 1; expression; non-small cell lung cancer; prognosis; survival; biomarker

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 17. 5. 2018 15:57, Soňa Böhmová

Anotace

V originále

Pemetrexed is an antifolate cytostatic agent targeting several folate-dependent enzymatic pathways, widely used in the treatment of locally advanced or metastatic stage non-small cell lung cancer. Aside from the non-squamous histology, there is still no available molecular biomarker predicting treatment efficacy of pemetrexed-based chemotherapy. The aim of our retrospective study was to evaluate the association of thyroid transcription factor 1 expression with outcome of a large cohort of patients with non-squamous non-small cell lung cancer treated with pemetrexed. We retrospectively analysed clinical data of 463 patients with advanced-stage non-small cell lung cancer (IIIB or IV) treated with pemetrexed-based chemotherapy. Thyroid transcription factor 1 expression was assessed using indirect immunohistochemical detection in formalin-fixed paraffin-embedded tumour tissue at the time of diagnosis. Thyroid transcription factor 1 expression was detected in the tumour tissue from 76.0% of patients, and tumours from 24.0% of patients were thyroid transcription factor 1 negative. The median progression-free survival and overall survival for patients with thyroid transcription factor 1 positive tumours were 4.8 and 11.8 months compared to 2.8 and 8.3 months for those with thyroid transcription factor 1 negative tumours (p = 0.001 and p < 0.001). The multivariable Cox proportional hazards model revealed that thyroid transcription factor 1 expression was significantly associated with progression-free survival (hazard ratio = 1.57, p < 0.001) and also with overall survival (hazard ratio = 1.73, p < 0.001). In conclusion, the results of the conducted retrospective study suggest that the thyroid transcription factor 1 expression was independently associated with progression-free survival and overall survival in patients with advanced-stage nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.

Citovat

FIALA, Ondrej; Milos PESEK; Jana SKŘIČKOVÁ; Vitezslav KOLEK; Frantisek SALAJKA; Marcela TOMÍŠKOVÁ; Monika ŠATÁNKOVÁ; Juraj KULTAN; Jana KULISKOVA; Martin SVATON; Michal HRNCIARIK; Karel HEJDUK; Renata CHLOUPKOVÁ; Ondrej TOPOLCAN; Helena HORNYCHOVA; Marketa NOVA; Ales RYSKA a Jindrich FINEK. Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. Tumor Biology. Dordrecht: Springer, 2017, roč. 39, č. 2, s. 1-8. ISSN 1010-4283. Dostupné z: https://doi.org/10.1177/1010428317691186.

@article{1378737,
   author = {Fiala, Ondrej and Pesek, Milos and Skřičková, Jana and Kolek, Vitezslav and Salajka, Frantisek and Tomíšková, Marcela and Šatánková, Monika and Kultan, Juraj and Kuliskova, Jana and Svaton, Martin and Hrnciarik, Michal and Hejduk, Karel and Chloupková, Renata and Topolcan, Ondrej and Hornychova, Helena and Nova, Marketa and Ryska, Ales and Finek, Jindrich},
   article_location = {Dordrecht},
   article_number = {2},
   doi = {https://doi.org/10.1177/1010428317691186},
   keywords = {Thyroid transcription factor 1; expression; non-small cell lung cancer; prognosis; survival; biomarker},
   language = {eng},
   issn = {1010-4283},
   journal = {Tumor Biology},
   title = {Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy},
   volume = {39},
   year = {2017}
}

TY  - JOUR
ID  - 1378737
AU  - Fiala, Ondrej - Pesek, Milos - Skřičková, Jana - Kolek, Vitezslav - Salajka, Frantisek - Tomíšková, Marcela - Šatánková, Monika - Kultan, Juraj - Kuliskova, Jana - Svaton, Martin - Hrnciarik, Michal - Hejduk, Karel - Chloupková, Renata - Topolcan, Ondrej - Hornychova, Helena - Nova, Marketa - Ryska, Ales - Finek, Jindrich
PY  - 2017
TI  - Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy
JF  - Tumor Biology
VL  - 39
IS  - 2
SP  - 1-8
EP  - 1-8
PB  - Springer
SN  - 10104283
KW  - Thyroid transcription factor 1
KW  - expression
KW  - non-small cell lung cancer
KW  - prognosis
KW  - survival
KW  - biomarker
N2  - Pemetrexed is an antifolate cytostatic agent targeting several folate-dependent enzymatic pathways, widely used in the treatment of locally advanced or metastatic stage non-small cell lung cancer. Aside from the non-squamous histology, there is still no available molecular biomarker predicting treatment efficacy of pemetrexed-based chemotherapy. The aim of our retrospective study was to evaluate the association of thyroid transcription factor 1 expression with outcome of a large cohort of patients with non-squamous non-small cell lung cancer treated with pemetrexed. We retrospectively analysed clinical data of 463 patients with advanced-stage non-small cell lung cancer (IIIB or IV) treated with pemetrexed-based chemotherapy. Thyroid transcription factor 1 expression was assessed using indirect immunohistochemical detection in formalin-fixed paraffin-embedded tumour tissue at the time of diagnosis. Thyroid transcription factor 1 expression was detected in the tumour tissue from 76.0% of patients, and tumours from 24.0% of patients were thyroid transcription factor 1 negative. The median progression-free survival and overall survival for patients with thyroid transcription factor 1 positive tumours were 4.8 and 11.8 months compared to 2.8 and 8.3 months for those with thyroid transcription factor 1 negative tumours (p = 0.001 and p < 0.001). The multivariable Cox proportional hazards model revealed that thyroid transcription factor 1 expression was significantly associated with progression-free survival (hazard ratio = 1.57, p < 0.001) and also with overall survival (hazard ratio = 1.73, p < 0.001). In conclusion, the results of the conducted retrospective study suggest that the thyroid transcription factor 1 expression was independently associated with progression-free survival and overall survival in patients with advanced-stage nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.
ER  -

FIALA, Ondrej; Milos PESEK; Jana SKŘIČKOVÁ; Vitezslav KOLEK; Frantisek SALAJKA; Marcela TOMÍŠKOVÁ; Monika ŠATÁNKOVÁ; Juraj KULTAN; Jana KULISKOVA; Martin SVATON; Michal HRNCIARIK; Karel HEJDUK; Renata CHLOUPKOVÁ; Ondrej TOPOLCAN; Helena HORNYCHOVA; Marketa NOVA; Ales RYSKA a Jindrich FINEK. Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. \textit{Tumor Biology}. Dordrecht: Springer, 2017, roč.~39, č.~2, s.~1-8. ISSN~1010-4283. Dostupné z: https://doi.org/10.1177/1010428317691186.

Přehled o publikaci